U.S. Hemophilia Treatment Market Poised to Grow at a Robust Pace Due to Rising Prevalence of Hemophilia

U.S. Hemophilia Treatment Market Poised to Grow at a Robust Pace Due to Rising Prevalence of Hemophilia

The U.S. hemophilia treatment market has witnessed significant growth over the past few years owing to the rising prevalence of hemophilia A and B disorders in the country. Hemophilia is a genetic bleeding disorder caused due to deficiency of coagulation factors VIII or IX in the blood which prevents normal clotting of the blood. There are two major types of hemophilia - hemophilia A caused due to factor VIII deficiency and hemophilia B caused due to factor IX deficiency. Hemophilia treatments involve replacement therapy using plasma-derived or recombinant coagulation factor concentrates to prevent and control bleeding episodes. Increasing awareness regarding hemophilia treatment options and advantages of prophylactic treatment over on-demand treatment are augmenting the adoption of hemophilia medicines. In addition, favorable reimbursement policies for hemophilia treatment in the US is also expected to drive the market growth.

The U.S. Hemophilia Treatment Market Size is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the U.S. hemophilia treatment are Takeda Pharmaceutical Company Limited, Sanofi, Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc. and Biogen Inc. among others. Takeda Pharmaceutical Company Limited dominates the U.S. hemophilia market with its flagship brands such as Advate, Adynovate and Xyntha portfolio. Sanofi holds the second position with its hemophilia products such as Alprolix and Eloctate gaining significant market share in the country.

Availability of extended half-life factor therapies offering better protection against bleeding episodes compared to conventional factor replacement therapies is expected to present lucrative growth opportunities for hemophilia drug manufacturers in the US market. In addition, rising awareness about prophylactic treatment as the primary line of treatment for hemophilia patients will further drive the preference for long-acting factor therapies in the country.

Major hemophilia drug manufacturers are undertaking various strategic initiatives such as collaborations, acquisitions and new product launches to expand their geographic presence and product portfolio across the US. For instance, in 2020, Takeda Pharmaceutical acquired publicly traded homozygous hemophilia drug manufacturer Shire plc, diversifying its hemophilia portfolio in the US market.

Market Drivers

Rising prevalence of hemophilia disorders: The prevalence of hemophilia A and B is rising in the US due to increasing diagnosis rates, improved treatment options and growing life expectancy of hemophilia patients. Higher disease prevalence will further drive the demand for hemophilia medicines in the country.

Market Restrain

High cost of treatment: Hemophilia treatments involve lifelong therapy and prophylactic factor replacement therapy is very expensive. High drug costs pose significant affordability challenges for patients without adequate insurance coverage thereby restrainting the market growth.

Segment Analysis 

The U.S. hemophilia treatment market is dominated by the hemophilia A sub segment. Hemophilia A accounts for about 80% of the total hemophilia patients in the U.S as it is the most common type of hemophilia. Hemophilia A results from a deficiency of clotting factor VIII in the blood which leads to easy or excessive bleeding from minor cuts, bruises or injury. The higher prevalence of hemophilia A makes it the dominating sub segment in the U.S hemophilia treatment market.

Global Analysis

The North America region dominates the global hemophilia treatment market and is expected to continue its dominance during the forecast period. This is due to the increasing prevalence of hemophilia in the region coupled with growing awareness regarding disease treatment and management. Availability of advanced treatment options and high healthcare expenditure also support the growth of the hemophilia treatment market in North America. The U.S. represents the major market for hemophilia treatment in the region due to presence of developed healthcare infrastructure and key market players.

What Are The Key Data Covered In This U.S. Hemophilia Treatment Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the U.S. Hemophilia Treatment's growth between 2024 and 2031.

:- Accurate calculation of the size of the U.S. Hemophilia Treatment and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- U.S. Hemophilia Treatment Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of U.S. Hemophilia Treatment vendors

FAQ’s

Q.1 What are the main factors influencing the U.S. Hemophilia Treatment?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top U.S. Hemophilia Treatment companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the U.S. Hemophilia Treatment’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://www.marketwebjournal.com/u-s-hemophilia-treatment-market-trend-size-and-demand-2/